Company intelligence / Profile preview

NeuGATE Theranostics

Houston, Texas, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

NeuGATE Theranostics is developing NG101m, an oral small molecule adjuvant therapy intended to be used alongside standard-of-care temozolomide and radiation for newly diagnosed glioblastoma multiforme. The first-in-human trial is planned but not yet recruiting as of early/mid 2025. No published clinical results are available.

Therapeutic areas: Oncology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

NG101m

Partnerships

RhoTauPharma lists NeuGATE Theranostics among its recent clients/collaborators for regulatory/pharmaceutical development support.

Beyond the preview

Go deeper on NeuGATE Theranostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuGATE Theranostics.